This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Lactoferricin and pLF1 inhibited TMPRSS2 activity and SARS-CoV-2 infection.
Why it matters
As COVID-19 continues to pose a global health threat, finding effective antiviral therapies is crucial. This research highlights potential new treatments that could complement existing vaccines.
How the study worked
The study tested lactoferricin and synthetic peptides for their ability to block TMPRSS2 and SARS-CoV-2 infection in laboratory conditions.
What this study cannot tell us
The study was conducted in vitro, so results may not directly translate to clinical effectiveness in humans.
Read the original research
Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.
Frontiers in immunology, 13, 958581
Citation
Ohradanova-Repic, Anna; Skrabana, Rostislav; Gebetsberger, Laura; Tajti, Gabor; Baráth, Peter; Ondrovičová, Gabriela; Praženicová, Romana; Jantova, Nikola; Hrasnova, Patricia; Stockinger, Hannes; Leksa, Vladimir. (2022). Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.. Frontiers in immunology, 13, 958581. https://doi.org/10.3389/fimmu.2022.958581